Centrexion Therapeutics changes its mind on initial public offering
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
Centrexion’s $67M Series D round to fund Phase 3 pain studies
Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Centrexion nabs three non-opioid pain drugs from Boehringer Ingelheim
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.